Xencor Inc. (NASDAQ:XNCR) shares hit a new 52-week high during mid-day trading on Friday . The company traded as high as $22.46 and last traded at $22.13, with a volume of 134,926 shares changing hands. The stock had previously closed at $21.50.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Xencor from a “hold” rating to a “buy” rating and set a $21.00 price target on the stock in a report on Tuesday, July 5th. Canaccord Genuity restated a “buy” rating on shares of Xencor in a report on Tuesday, June 28th. Leerink Swann restated an “outperform” rating and set a $18.00 price target on shares of Xencor in a report on Wednesday, June 29th. Wedbush restated an “outperform” rating and set a $27.00 price target on shares of Xencor in a report on Tuesday, June 28th. Finally, TheStreet upgraded Xencor from a “sell” rating to a “hold” rating in a report on Monday, April 25th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $23.29.

The stock has a market cap of $915.55 million and a PE ratio of 23.85. The firm has a 50-day moving average price of $17.56 and a 200-day moving average price of $13.84.

Xencor (NASDAQ:XNCR) last posted its quarterly earnings data on Tuesday, August 2nd. The biopharmaceutical company reported $1.13 earnings per share for the quarter, topping the consensus estimate of ($0.18) by $1.31. The company earned $66 million during the quarter, compared to analyst estimates of $7.43 million. Analysts expect that Xencor Inc. will post $0.72 earnings per share for the current fiscal year.

In related news, CEO Bassil I. Dahiyat sold 45,886 shares of the company’s stock in a transaction dated Tuesday, May 24th. The shares were sold at an average price of $13.00, for a total value of $596,518.00. Following the completion of the sale, the chief executive officer now owns 358,186 shares of the company’s stock, valued at $4,656,418. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. Its segment is related to the development of pharmaceutical products. It uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.